HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is please to announce that the presentation of NX-1207 clinical study data at the AUA South Central Section annual meeting in Santa Ana Pueblo, NM was featured in the Urology Times, the widely distributed and most read publication of U.S. urologists. At the meeting, Raphael Wurzel, MD, reviewed clinical data from the most recent NX-1207 trial that showed that treatment with a single dose of NX-1207 significantly improved BPH symptom scores and significantly reduced prostate size after 90 days.
